Overview
OKYO market data
Price History
OKYO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.06 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.34 – $3.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $78.3M · P/B 5.08.
Company News
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per ShareBenzinga · Jul 28, 2026, 11:08 AM
OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 SharesBenzinga · Jul 23, 2026, 4:03 PM
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per ShareBenzinga · Jul 23, 2026, 11:01 AM
OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per ShareBenzinga · Jul 22, 2026, 2:02 PM
OKYO Pharma Says Chief Medical Officer, Flavio Mantelli, Purchases 20,000 Of Its Ordinary Shares On NASDAQ At $1.40 Per ShareBenzinga · Jul 22, 2026, 11:08 AM
OKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per ShareBenzinga · Jul 21, 2026, 11:03 AM
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 PlansGlobenewswire Inc · Jul 20, 2026, 12:02 PM
OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA FeedbackBenzinga · Jul 20, 2026, 11:16 AM
HC Wainwright & Co. Maintains Buy on OKYO Pharma, Lowers Price Target to $5Benzinga · Jul 13, 2026, 10:10 AM
OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCPBenzinga · Jul 8, 2026, 11:10 AM